Back to Search
JEFFREY BERENSON, MD
MD
Internal Medicine Physician
NPI: 1902828619IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G39574(CA)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO SCHOOL OF MEDICINE
Class of 1978
Research & Publications (20)
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
PMID 19226361·Eur J Haematol·2009
3-trial
Hematology: Bortezomib in newly diagnosed multiple myeloma.
PMID 19390550·Nat Rev Clin Oncol·2009
8-other
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
PMID 19188182·Clin Cancer Res·2009
3-trial
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
PMID 18829511·Clin Cancer Res·2008
3-trial
Comparison of twin and autologous transplants for multiple myeloma.
PMID 18804041·Biol Blood Marrow Transplant·2008
3-trial
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
PMID 18463870·Ann Hematol·2008
3-trial
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
PMID 17363530·Clin Cancer Res·2007
3-trial
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
PMID 17229334·Clin Lymphoma Myeloma·2006
6-review
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
PMID 17010047·Br J Haematol·2006
3-trial
Treatment strategies for skeletal complications of cancer.
PMID 16969118·Cancer Biol Ther·2006
6-review
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
PMID 16418495·J Clin Oncol·2006
3-trial
Recommendations for zoledronic acid treatment of patients with bone metastases.
PMID 15632252·Oncologist·2005
6-review
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
Safety and convenience of a 15-minute infusion of zoledronic acid.
PMID 15169987·Oncologist·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 45081 LITTLE LAKE STREET
MENDOCINO, CA 95460 - Phone
- (707) 937-1055
Quick Facts
- NPI
- 1902828619
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 48
- Publications
- 20
Are you this provider?
Claim Your Profile